Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs

China-based contract manufacturer WuXi AppTec has been the focal point of scrutiny from Congress for months. A House bill, the BIOSECURE Act, has labeled it a “company of concern” due to its alleged ties to the Chinese government and potential threat to U.S. national security. However, multiple biopharma companies depend on WuXi for critical research, development and manufacturing. The prospect of restricting WuXi’s vast scope of work has caused uncertainty in the market, but it has also opened the door potentially for some competitors to help fill the gap.